Drug Repurposing Hub Library @broadinstitute @MIT @Harvard
Reporter: Aviva Lev-Ari, PhD, RN and Irina Robu, PhD
CLAIMER: most valuable information for Drug Repurposing is found in the following LPBI Group three Intellectual Property Asset Classes
Our intellectual property “IP” consists of three classes of assets as described in detail within live links in the below, listed article.
- First, the Journal, an ongoing journal of curated, current biomedical research;
- Second, the books, a collection of 16 volumes of e-books available via Amazon in five specialties of Medicine: Cardiovascular, Genomics, Cancer, Immunology and Precision Medicine; and
- Third, real-time curation of biotech and medical conferences yielding an e-Proceedings at the end of the conference in One-click operation.
These three IP asset classes are described in details with live links in
eScientific Publishing a Case in Point: Evolution of Platform Architecture Methodologies and of Intellectual Property Development (Content Creation by Curation) Business Model
The Drug Repurposing Hub: A next-generation drug library and information resource
M Corsello, Steven & A Bittker, Joshua & Liu, Zihan & Gould, Joshua & McCarren, Patrick & E Hirschman, Jodi & E Johnston, Stephen & Vrcic, Anita & Wong, Bang & Khan, Mariya & Asiedu, Jacob & Narayan, Rajiv & C Mader, Christopher & Subramanian, Aravind & R Golub, Todd. (2017). The Drug Repurposing Hub: A next-generation drug library and information resource. Nature Medicine. 23. 405-408. 10.1038/nm.4306.
… Published on January 3, 2018 as DOI: 10.1124/mol.117. Downloaded from additional source, we used data from the Broad repurposing hub ( Corsello et al, 2017), which employed high throughput screening to characterize drug-target interactions of approved drugs, natural products and nutraceuticals along with other entities. Our analysis yielded a list of currently ‘druggable’ GPCRs and the drugs that target them. …… Using a range of ~500 (conservative estimate) to ~700 GPCR-targeted drugs, we estimate that between ~25% and ~36% of approved drugs target GPCRs, with the upper figure the more likely. As additional studies such as the Broad repurposing initiative ( Corsello et al, 2017) characterize GPCR-drug interactions in more detail, we anticipate a growth in this number, as secondary interactions between GPCRs and drugs are defined ( Allen and Roth, 2011). IUPHAR lists more druggable GPCRs than CHEMBL or DRUGBANK but has the smallest number of GPCR-related and overall approved drugs ( Figure 3C shows the number of GPCR-targeted drugs based on target-ligand interactions annotated by either IUPHAR or CHEMBL; of the 476 such drugs listed in one or both sources, only a portion are common to both (50%). …
Drug Repurposing Hub Library @broadinstitute @MIT @Harvard
To date there has not been a systematic effort to identify such opportunities, limited in part by the lack of a comprehensive library of clinical compounds suitable for testing. To address this challenge, we hand-curated a collection of 4,707 compounds, experimentally confirmed their identity, and annotated them with literature-reported targets. The collection includes 3,422 drugs that are marketed around the world or that have been tested in human clinical trials. Compounds were obtained from more than 50 chemical vendors and the purity of each sample was established. We have thus established a blueprint for others to easily assemble such a repurposing library, and we have created an online Drug Repurposing Hub (www.broadinstitute.org/repurposing) containing detailed annotation for each of the compounds.
SOURCE
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568558/
The Drug Repurposing Hub: a next-generation drug library and information resource
- Cancer based pharmacogenomics network supported with scientific evidences: from the view of drug repurposing.[BioData Min. 2015]
- Open-source approaches for the repurposing of existing or failed candidate drugs: learning from and applying the lessons across diseases.[Drug Des Devel Ther. 2013]
- The Resource Hub: an innovative e-information service delivery model addressing mental health knowledge management.[Australas Psychiatry. 2009]
- A weighted and integrated drug-target interactome: drug repurposing for schizophrenia as a use case.[BMC Syst Biol. 2015]
- Drug Repurposing Is a New Opportunity for Developing Drugs against Neuropsychiatric Disorders.[Schizophr Res Treatment. 2016]
Leave a Reply